Skip to search formSkip to main contentSkip to account menu

recurrent neuroblastoma

Known as: Relapsed Neuroblastoma, neuroblastoma, recurrent 
The reemergence of neuroblastoma after a period of remission.
National Institutes of Health

Related topics

Related topics

15 relations
Embryonic CellEmbryonic tissueHemorrhageLoss of Chromosome 1p

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Clinically Relevant Biomarker Discovery in High-Risk Recurrent Neuroblastoma
Neuroblastoma is a pediatric cancer of the developing sympathetic nervous system. High-risk neuroblastoma patients typically… 
Review
2017
Review
2017
Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.
Review
2017
Review
2017
Anti-GD2 immunotherapy for neuroblastoma
ABSTRACT Introduction: Current therapeutic approaches for high-risk neuroblastoma (HR-NB) include high-dose chemotherapy, surgery… 
Highly Cited
2015
Highly Cited
2015
A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma
Abstract Antigen-specific immunotherapy was studied in a multi-institutional phase 1/2 study by combining decitabine (DAC… 
Review
2008
Review
2008
Radiolabeled metaiodobenzylguanidine for imaging and therapy of neuroblastoma.
Neuroblastoma is an embryonic tumor of the peripheral sympathetic nervous system, and is able to take up, store and secrete… 
Highly Cited
2007
Highly Cited
2007
Topotecan, cyclophosphamide, and etoposide (TCE) in the treatment of high-risk neuroblastoma. Results of a phase-II trial
PurposeRelapsed high-risk neuroblastoma patients still have a poor prognosis. This phase-II trial assessed a new topotecan… 
Highly Cited
2006
Highly Cited
2006
A Phase I Clinical Trial of the hu14.18-IL2 (EMD 273063) as a Treatment for Children with Refractory or Recurrent Neuroblastoma and Melanoma: a Study of the Children's Oncology Group
Purpose: Evaluate the clinical safety, toxicity, immune activation/modulation, and maximal tolerated dose of hu14.18-IL2 (EMD… 
Highly Cited
2005
Highly Cited
2005
Feasibility of dosimetry-based high-dose 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma.
INTRODUCTION (131)I-meta iodobenzylguanidine ((131)I-mIBG) therapy is established palliation for relapsed neuroblastoma. The… 
Review
2003
Review
2003
Secondary Myelodysplastic Syndrome and Leukemia Following 131I-Metaiodobenzylguanidine Therapy for Relapsed Neuroblastoma
Purpose To describe three patients with secondary leukemia after treatment with 131I-metaiodobenzylguanidine (MIBG) for… 
Review
1995
Review
1995
High-dose intravenous melphalan: a review.
PURPOSE To review the clinical pharmacology and clinical trials that have used intravenous (IV) high-dose melphalan (HDM… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)